Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine hydrochloride for prevention of postoperative pulmonary complications in high-risk non-cardiothoracic surgery patients
ChiCTR2300077508Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of penehyclidine in postoperative respiratory complications (PRC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Incidence of postoperative pulmonary complications within 7 days after surgery. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ChiCTR2300077508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077508.